 Sunita Sharma
Concepts (188)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 31 | 2023 | 2156 | 5.550 |
Why?
| | Gastroesophageal Reflux | 2 | 2023 | 239 | 1.370 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 4 | 2022 | 1114 | 1.100 |
Why?
| | Lung | 14 | 2023 | 3588 | 1.080 |
Why?
| | Adrenal Cortex Hormones | 3 | 2021 | 508 | 1.040 |
Why?
| | Adrenergic beta-Agonists | 2 | 2020 | 127 | 1.010 |
Why?
| | Genome-Wide Association Study | 7 | 2023 | 1314 | 0.960 |
Why?
| | Sleep Apnea, Obstructive | 2 | 2022 | 237 | 0.760 |
Why?
| | Gene Expression Regulation | 3 | 2022 | 2408 | 0.750 |
Why?
| | Smoke | 2 | 2023 | 135 | 0.740 |
Why?
| | Dyspnea | 1 | 2022 | 202 | 0.730 |
Why?
| | GTP Phosphohydrolases | 1 | 2020 | 68 | 0.720 |
Why?
| | Gene Expression Profiling | 6 | 2016 | 1588 | 0.700 |
Why?
| | Epigenesis, Genetic | 3 | 2023 | 546 | 0.700 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2022 | 600 | 0.680 |
Why?
| | Exercise Test | 1 | 2022 | 541 | 0.670 |
Why?
| | Dermatitis, Atopic | 1 | 2023 | 334 | 0.660 |
Why?
| | Marijuana Use | 1 | 2022 | 160 | 0.660 |
Why?
| | Genomics | 3 | 2020 | 658 | 0.660 |
Why?
| | DNA Methylation | 3 | 2023 | 512 | 0.660 |
Why?
| | MicroRNAs | 2 | 2023 | 627 | 0.650 |
Why?
| | Glucocorticoids | 2 | 2020 | 544 | 0.640 |
Why?
| | Dietary Supplements | 3 | 2019 | 466 | 0.600 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2018 | 96 | 0.590 |
Why?
| | Genetic Predisposition to Disease | 8 | 2023 | 2227 | 0.580 |
Why?
| | Ascorbic Acid | 1 | 2017 | 118 | 0.570 |
Why?
| | Gene Expression Regulation, Developmental | 4 | 2016 | 805 | 0.520 |
Why?
| | Quantitative Trait Loci | 1 | 2017 | 325 | 0.520 |
Why?
| | Cannabis | 1 | 2022 | 381 | 0.510 |
Why?
| | Biomarkers | 3 | 2022 | 3549 | 0.500 |
Why?
| | Humans | 42 | 2023 | 117053 | 0.500 |
Why?
| | alpha-N-Acetylgalactosaminidase | 1 | 2014 | 3 | 0.490 |
Why?
| | Genes, Developmental | 1 | 2014 | 2 | 0.480 |
Why?
| | Pulmonary Emphysema | 1 | 2017 | 318 | 0.470 |
Why?
| | Fatty Acid Desaturases | 1 | 2014 | 34 | 0.470 |
Why?
| | Polymorphism, Single Nucleotide | 7 | 2023 | 2038 | 0.470 |
Why?
| | Vitamin B Complex | 1 | 2013 | 37 | 0.460 |
Why?
| | Dexamethasone | 1 | 2015 | 313 | 0.440 |
Why?
| | Environmental Exposure | 2 | 2014 | 385 | 0.430 |
Why?
| | Food | 1 | 2013 | 160 | 0.420 |
Why?
| | Citrulline | 2 | 2023 | 38 | 0.390 |
Why?
| | Phenotype | 5 | 2023 | 2891 | 0.380 |
Why?
| | Epidemiologic Studies | 1 | 2011 | 58 | 0.380 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2014 | 977 | 0.380 |
Why?
| | Bronchodilator Agents | 2 | 2023 | 249 | 0.330 |
Why?
| | Pyroglyphidae | 1 | 2008 | 17 | 0.330 |
Why?
| | Wnt Proteins | 1 | 2009 | 140 | 0.320 |
Why?
| | Obesity | 4 | 2022 | 2661 | 0.310 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2008 | 159 | 0.300 |
Why?
| | Child | 11 | 2023 | 18877 | 0.250 |
Why?
| | Lung Diseases | 2 | 2016 | 693 | 0.250 |
Why?
| | Respiratory Function Tests | 2 | 2020 | 523 | 0.250 |
Why?
| | Principal Component Analysis | 3 | 2016 | 181 | 0.250 |
Why?
| | Bone Marrow Transplantation | 1 | 2005 | 244 | 0.240 |
Why?
| | Administration, Inhalation | 2 | 2020 | 642 | 0.240 |
Why?
| | Double-Blind Method | 4 | 2016 | 1670 | 0.230 |
Why?
| | Placenta | 2 | 2023 | 628 | 0.220 |
Why?
| | Mendelian Randomization Analysis | 1 | 2023 | 48 | 0.220 |
Why?
| | Case-Control Studies | 3 | 2022 | 3099 | 0.210 |
Why?
| | Risk Factors | 6 | 2022 | 8873 | 0.210 |
Why?
| | Causality | 1 | 2023 | 110 | 0.210 |
Why?
| | Aryldialkylphosphatase | 1 | 2022 | 20 | 0.210 |
Why?
| | Hospitalization | 2 | 2020 | 1762 | 0.200 |
Why?
| | Immunity | 1 | 2022 | 128 | 0.200 |
Why?
| | Symptom Flare Up | 1 | 2020 | 40 | 0.190 |
Why?
| | Male | 16 | 2023 | 56665 | 0.180 |
Why?
| | Exercise Tolerance | 1 | 2022 | 227 | 0.180 |
Why?
| | Fetus | 2 | 2016 | 703 | 0.180 |
Why?
| | Severity of Illness Index | 3 | 2020 | 2633 | 0.180 |
Why?
| | GTPase-Activating Proteins | 1 | 2020 | 71 | 0.180 |
Why?
| | Female | 17 | 2023 | 60635 | 0.180 |
Why?
| | Forced Expiratory Volume | 4 | 2019 | 517 | 0.180 |
Why?
| | Chemotaxis | 1 | 2020 | 133 | 0.180 |
Why?
| | Genetic Loci | 2 | 2023 | 279 | 0.180 |
Why?
| | Smoking | 2 | 2020 | 1457 | 0.170 |
Why?
| | Treatment Outcome | 4 | 2020 | 9257 | 0.170 |
Why?
| | Nedocromil | 2 | 2008 | 32 | 0.160 |
Why?
| | Interleukins | 1 | 2020 | 238 | 0.160 |
Why?
| | Particulate Matter | 1 | 2020 | 220 | 0.160 |
Why?
| | Administration, Oral | 1 | 2021 | 744 | 0.160 |
Why?
| | Vital Capacity | 2 | 2009 | 257 | 0.160 |
Why?
| | Guidelines as Topic | 1 | 2020 | 250 | 0.160 |
Why?
| | Air Pollution | 1 | 2020 | 184 | 0.160 |
Why?
| | Quality of Life | 3 | 2023 | 2374 | 0.150 |
Why?
| | Databases, Genetic | 2 | 2016 | 212 | 0.150 |
Why?
| | Histones | 1 | 2022 | 544 | 0.150 |
Why?
| | RNA, Messenger | 2 | 2023 | 2632 | 0.150 |
Why?
| | Child, Preschool | 3 | 2023 | 9323 | 0.140 |
Why?
| | Comorbidity | 1 | 2021 | 1487 | 0.140 |
Why?
| | Arginine | 3 | 2023 | 240 | 0.140 |
Why?
| | Folic Acid | 1 | 2017 | 161 | 0.140 |
Why?
| | Pregnancy | 4 | 2023 | 5653 | 0.140 |
Why?
| | Diagnosis, Differential | 1 | 2020 | 1341 | 0.140 |
Why?
| | Vitamins | 1 | 2017 | 156 | 0.140 |
Why?
| | Maternal Exposure | 1 | 2017 | 141 | 0.130 |
Why?
| | Betamethasone | 1 | 2015 | 19 | 0.130 |
Why?
| | Cadherins | 1 | 2017 | 180 | 0.130 |
Why?
| | Animals | 7 | 2018 | 32737 | 0.130 |
Why?
| | Neutrophils | 1 | 2020 | 1081 | 0.130 |
Why?
| | CCAAT-Enhancer-Binding Protein-delta | 1 | 2015 | 4 | 0.130 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2020 | 695 | 0.130 |
Why?
| | Tacrolimus Binding Proteins | 1 | 2015 | 17 | 0.130 |
Why?
| | Animals, Newborn | 2 | 2015 | 797 | 0.130 |
Why?
| | Oligonucleotide Array Sequence Analysis | 3 | 2016 | 761 | 0.120 |
Why?
| | Costa Rica | 1 | 2014 | 19 | 0.120 |
Why?
| | Respiratory Distress Syndrome, Newborn | 1 | 2015 | 99 | 0.120 |
Why?
| | Nitric Oxide | 1 | 2019 | 861 | 0.120 |
Why?
| | Prevalence | 1 | 2020 | 2300 | 0.120 |
Why?
| | Genetic Markers | 1 | 2015 | 338 | 0.120 |
Why?
| | Gestational Age | 3 | 2012 | 766 | 0.110 |
Why?
| | Cohort Studies | 4 | 2017 | 5051 | 0.110 |
Why?
| | Ornithine | 2 | 2023 | 21 | 0.110 |
Why?
| | Gene Expression | 1 | 2018 | 1466 | 0.110 |
Why?
| | Maternal Behavior | 1 | 2012 | 66 | 0.100 |
Why?
| | Epigenomics | 2 | 2023 | 106 | 0.100 |
Why?
| | Cotinine | 1 | 2012 | 74 | 0.100 |
Why?
| | Premature Birth | 1 | 2015 | 276 | 0.100 |
Why?
| | Morbidity | 2 | 2023 | 283 | 0.100 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2017 | 472 | 0.100 |
Why?
| | Sex Characteristics | 1 | 2016 | 648 | 0.100 |
Why?
| | Alleles | 2 | 2017 | 816 | 0.100 |
Why?
| | Transcriptome | 1 | 2016 | 756 | 0.090 |
Why?
| | Intestines | 1 | 2013 | 326 | 0.090 |
Why?
| | Mice, Inbred C57BL | 3 | 2015 | 4839 | 0.090 |
Why?
| | Vitamin D | 1 | 2013 | 345 | 0.090 |
Why?
| | Signal Transduction | 2 | 2020 | 4606 | 0.090 |
Why?
| | Computational Biology | 1 | 2013 | 540 | 0.090 |
Why?
| | Infant, Newborn | 2 | 2017 | 5170 | 0.090 |
Why?
| | Lung Neoplasms | 1 | 2021 | 2222 | 0.080 |
Why?
| | Bronchial Hyperreactivity | 1 | 2008 | 95 | 0.080 |
Why?
| | Budesonide | 1 | 2008 | 87 | 0.080 |
Why?
| | Spirometry | 1 | 2008 | 258 | 0.080 |
Why?
| | Genetic Association Studies | 1 | 2009 | 350 | 0.080 |
Why?
| | Adolescent | 3 | 2011 | 18215 | 0.070 |
Why?
| | Inflammation | 1 | 2018 | 2515 | 0.070 |
Why?
| | Transcription Factors | 1 | 2015 | 1557 | 0.070 |
Why?
| | United States | 2 | 2021 | 12381 | 0.070 |
Why?
| | Multivariate Analysis | 1 | 2011 | 1458 | 0.070 |
Why?
| | Microbiota | 1 | 2013 | 662 | 0.070 |
Why?
| | Mice | 4 | 2015 | 15309 | 0.070 |
Why?
| | Autopsy | 1 | 2005 | 86 | 0.060 |
Why?
| | Allergens | 1 | 2008 | 430 | 0.060 |
Why?
| | Adult | 6 | 2022 | 31003 | 0.060 |
Why?
| | Anti-Asthmatic Agents | 1 | 2008 | 349 | 0.060 |
Why?
| | Oxidative Stress | 2 | 2022 | 1148 | 0.060 |
Why?
| | Prospective Studies | 3 | 2023 | 6389 | 0.060 |
Why?
| | Albuterol | 1 | 2023 | 106 | 0.060 |
Why?
| | Whole Genome Sequencing | 1 | 2023 | 110 | 0.050 |
Why?
| | Quercetin | 1 | 2022 | 11 | 0.050 |
Why?
| | Fibroblast Growth Factors | 1 | 2023 | 165 | 0.050 |
Why?
| | Middle Aged | 4 | 2020 | 27173 | 0.050 |
Why?
| | Hydrogen Peroxide | 1 | 2022 | 296 | 0.050 |
Why?
| | Proof of Concept Study | 1 | 2019 | 45 | 0.040 |
Why?
| | Follow-Up Studies | 1 | 2008 | 4507 | 0.040 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2019 | 160 | 0.040 |
Why?
| | Young Adult | 3 | 2020 | 10675 | 0.040 |
Why?
| | Intubation, Intratracheal | 1 | 2020 | 220 | 0.040 |
Why?
| | Epithelial Cells | 1 | 2023 | 940 | 0.040 |
Why?
| | Early Detection of Cancer | 1 | 2021 | 356 | 0.040 |
Why?
| | Netherlands | 1 | 2016 | 65 | 0.040 |
Why?
| | Respiration, Artificial | 1 | 2020 | 540 | 0.040 |
Why?
| | Aged | 3 | 2020 | 19359 | 0.040 |
Why?
| | Intensive Care Units | 1 | 2020 | 630 | 0.030 |
Why?
| | Demography | 1 | 2017 | 269 | 0.030 |
Why?
| | Logistic Models | 1 | 2020 | 1877 | 0.030 |
Why?
| | Statistics as Topic | 1 | 2016 | 299 | 0.030 |
Why?
| | Pilot Projects | 1 | 2019 | 1395 | 0.030 |
Why?
| | Cytochrome P-450 CYP1B1 | 1 | 2012 | 5 | 0.030 |
Why?
| | Cytochrome P-450 CYP1A1 | 1 | 2012 | 9 | 0.030 |
Why?
| | Body Mass Index | 1 | 2020 | 2070 | 0.030 |
Why?
| | Enzyme Induction | 1 | 2012 | 90 | 0.030 |
Why?
| | Aryl Hydrocarbon Hydroxylases | 1 | 2012 | 42 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2022 | 4510 | 0.030 |
Why?
| | ROC Curve | 1 | 2012 | 460 | 0.020 |
Why?
| | Models, Animal | 1 | 2012 | 348 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 965 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2016 | 2480 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2020 | 6454 | 0.020 |
Why?
| | Up-Regulation | 1 | 2012 | 837 | 0.020 |
Why?
| | Age Factors | 1 | 2016 | 2951 | 0.020 |
Why?
| | Linear Models | 1 | 2011 | 802 | 0.020 |
Why?
| | Retrospective Studies | 1 | 2005 | 12825 | 0.020 |
Why?
| | Odds Ratio | 1 | 2011 | 981 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2012 | 1740 | 0.020 |
Why?
| | Cell Line | 1 | 2013 | 2670 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2012 | 1825 | 0.020 |
Why?
| | Liver | 1 | 2012 | 1744 | 0.020 |
Why?
| | Risk Assessment | 1 | 2011 | 3021 | 0.010 |
Why?
|
|
Sharma's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|